KALA BIO Inc (OQ:KALA)

Mar 29, 2024 08:00 am ET
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial results for the fourth...
Feb 26, 2024 08:00 am ET
KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference
KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Mark Iwicki, Chair and Chief...
Feb 06, 2024 08:00 am ET
KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that management will present at...
Jan 19, 2024 04:01 pm ET
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s Amended and Restated 2017 Equity Incentive Plan in accordance with Nasdaq Listing Rule...
Nov 13, 2023 08:00 am ET
KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update
KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research and development of innovative therapies for rare and severe diseases of the eye, today reported financial results for the third quarter ended...
Sep 20, 2023 04:01 pm ET
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s Amended and Restated 2017 Equity Incentive Plan in accordance with Nasdaq Listing Rule...
Sep 05, 2023 08:00 am ET
KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference
KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that management will present at...
Aug 15, 2023 10:20 am ET
Sidoti Events, LLC’s Virtual August Micro-Cap Conference
NEW YORK, NY / ACCESSWIRE / August 15, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day August Micro-Cap Conference taking place Wednesday and Thursday, August 16-17, 2023. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links.
Aug 04, 2023 08:00 am ET
KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update
KALA BIO, Inc. (Nasdaq:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial results for the second...
Aug 02, 2023 04:01 pm ET
KALA BIO to Participate in Upcoming Investor Conferences in August
KALA BIO, Inc. (Nasdaq:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that management will participate...
Aug 02, 2023 08:00 am ET
Kala Pharmaceuticals Announces Name Change to KALA BIO
Kala Pharmaceuticals, Inc. (Nasdaq:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that it will change...
Jul 19, 2023 04:01 pm ET
Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s Amended and Restated 2017 Equity Incentive Plan in accordance with Nasdaq...
Jun 23, 2023 04:01 pm ET
Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options and restricted stock units (RSUs) to new employees as inducement awards outside the Company’s Amended and Restated 2017 Equity Incentive...
Jun 02, 2023 08:00 am ET
Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that it will present...
May 09, 2023 08:00 am ET
Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial results for...
Apr 28, 2023 08:00 am ET
Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that the California...
Apr 12, 2023 08:00 am ET
Kala Pharmaceuticals Receives FDA Fast Track Designation for KPI-012, a Human MSC-S Therapy for Persistent Corneal Epithelial Defect
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that the U.S. Food...
Mar 29, 2023 08:00 am ET
Kala Pharmaceuticals Appoints Dr. Francis Mah as Chief Medical Advisor
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced the appointment of...
Mar 27, 2023 08:00 am ET
Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced positive safety data...
Mar 08, 2023 04:01 pm ET
Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that it will present...
Mar 03, 2023 08:00 am ET
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial results for...
Jan 05, 2023 07:47 am ET
Thinking about buying stock in Novocure, Zai Lab, Kala Pharmaceuticals, Orchard Therapeutics, or CytomX Therapeutics?
NEW YORK, Jan. 5, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NVCR, ZLAB, KALA, ORTX, and CTMX.
Dec 30, 2022 07:40 am ET
Thinking about buying stock in Palisade Bio, Kala Pharmaceuticals, F-Star Therapeutics, Nuwellis, or TG Therapeutics?
NEW YORK, Dec. 30, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PALI, KALA, FSTX, NUWE, and TGTX.
Dec 29, 2022 07:57 am ET
Thinking about buying stock in Baudax Bio, Kala Pharmaceuticals, GlycoMimetics, Pagaya Technologies, or Transcode Therapeutics?
NEW YORK, Dec. 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BXRX, KALA, GLYC, PGY, and RNAZ.
Dec 28, 2022 07:36 am ET
Thinking about buying stock in Jounce Therapeutics, Kala Pharmaceuticals, Nano-X Imaging, F-Star Therapeutics, or Pagaya Technologies?
NEW YORK, Dec. 28, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JNCE, KALA, NNOX, FSTX, and PGY.
Dec 27, 2022 04:01 pm ET
Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that the U.S. Food and Drug...
Nov 28, 2022 04:02 pm ET
Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced the submission of an...
Nov 28, 2022 04:01 pm ET
Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that it has entered into a...
Nov 09, 2022 10:14 am ET
Thinking about buying stock in Kala Pharmaceuticals, Coinbase Global, Apple, Carvana, or Nio?
NEW YORK, Nov. 9, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KALA, COIN, AAPL, CVNA, and NIO.
Nov 08, 2022 08:00 am ET
Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today reported financial results for the third...
Nov 01, 2022 07:30 am ET
Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors
Kala Pharmaceuticals, Inc. (NASDAQ: KALA) (“Kala” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced the...
Oct 20, 2022 07:30 am ET
Kala Pharmaceuticals Announces Reverse Stock Split
Kala Pharmaceuticals, Inc. (NASDAQ: KALA) (“Kala” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that...
Sep 06, 2022 08:00 am ET
Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that it will present at the H.C....
Aug 19, 2022 04:01 pm ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as an inducement award outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule...
Aug 18, 2022 04:01 pm ET
Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) (“Kala” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that...
Aug 11, 2022 07:00 am ET
Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today reported financial results for the second...
Aug 08, 2022 09:00 am ET
Kala Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that it will report second...
Aug 04, 2022 04:01 pm ET
Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in August
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that management will participate...
Jul 22, 2022 04:01 pm ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule...
Jul 11, 2022 08:00 am ET
Kala Pharmaceuticals Completes Sale of EYSUVIS® and INVELTYS® to Alcon Inc
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, announced today that it has completed the sale...
Jun 17, 2022 04:01 pm ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4)....
Jun 02, 2022 08:00 am ET
Kala Pharmaceuticals to Present at Jefferies Healthcare Conference
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the...
May 23, 2022 12:01 am ET
Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it has entered into a...
May 16, 2022 07:00 am ET
Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the first...
May 09, 2022 08:00 am ET
Kala Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report first quarter...
May 03, 2022 09:31 am ET
Thinking about buying stock in Graphite Bio, Kala Pharmaceuticals, ATAI Life Sciences, Talos Energy, or Borr Drilling?
NEW YORK, May 3, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GRPH, KALA, ATAI, TALO, and BORR.
May 03, 2022 08:00 am ET
Kala Pharmaceuticals Announces New Commercial and Medicare Coverage for EYSUVIS®
Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that the largest Pharmacy Benefit...
May 01, 2022 09:00 am ET
Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported clinical data from a Phase 1b trial...
Apr 04, 2022 04:01 pm ET
Kala Pharmaceuticals to Present Phase 1b Clinical Data for KPI-012 in Patients with PCED at 2022 ARVO Annual Meeting
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present data from a...
Mar 29, 2022 07:00 am ET
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the fourth...
Mar 23, 2022 08:00 am ET
Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report fourth quarter...
Mar 14, 2022 08:30 am ET
Thinking about buying stock in Volt Information Sciences, Arcadia Biosciences, Deutsche Bank, Biofrontera, or Kala Pharmaceuticals?
NEW YORK, March 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VOLT, RKDA, DB, BFRI, and KALA.
Mar 10, 2022 07:45 am ET
Thinking about buying stock in Tiziana Life Sciences, Indonesia Energy, US Well Services, Kala Pharmaceuticals, or Nine Energy Service?
NEW YORK, March 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TLSA, INDO, USWS, KALA, and NINE.
Mar 08, 2022 08:00 am ET
Kala Pharmaceuticals Announces EYSUVIS® Now Covered on UnitedHealthcare Commercial and Cigna Medicare
Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that UnitedHealthcare, one of the...
Feb 18, 2022 04:00 pm ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule...
Dec 17, 2021 04:01 pm ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4)....
Nov 18, 2021 04:01 pm ET
Kala Pharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4)....
Nov 15, 2021 08:47 am ET
Kala Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the third...
Nov 15, 2021 08:45 am ET
Kala Pharmaceuticals Acquires Combangio, Expanding its Pipeline with a Clinical-Stage Novel Biologic for the Treatment of Persistent Corneal Epithelial Defect (PCED) and other Rare Ocular Surface Dise
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it has acquired Combangio,...
Nov 15, 2021 07:00 am ET
Kala Pharmaceuticals Announces Time Change for Third Quarter 2021 Financial Results Conference Call
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it has changed the time of its...
Nov 11, 2021 08:00 am ET
Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in November 2021
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that management will participate in...
Nov 08, 2021 04:01 pm ET
Kala Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report third quarter...
Oct 22, 2021 04:01 pm ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4)....
Oct 18, 2021 08:00 am ET
Kala Pharmaceuticals Announces Appointment of C. Daniel Myers to Board of Directors
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced the appointment of C. Daniel Myers...
Sep 21, 2021 04:01 pm ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4)....
Sep 07, 2021 08:00 am ET
Kala Pharmaceuticals to Present at Upcoming Investor Conferences in September 2021
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that management will participate in...
Aug 30, 2021 09:31 am ET
Thinking about buying stock in Marqeta, Lexicon Pharmaceuticals, Kala Pharmaceuticals, Owlet, or New Oriental Education?
NEW YORK, Aug. 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MQ, LXRX, KALA, OWLT, and EDU.
Aug 18, 2021 04:01 pm ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4)....
Aug 05, 2021 07:00 am ET
Kala Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the second...
Aug 04, 2021 08:00 am ET
Kala Pharmaceuticals to Present at Upcoming Investor Conferences in August
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that management will participate in the following...
Jul 29, 2021 08:00 am ET
Kala Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report second quarter 2021 financial...
Jul 19, 2021 04:01 pm ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4)....
Jun 18, 2021 04:01 pm ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Jun 03, 2021 07:00 am ET
Kala Pharmaceuticals Announces EYSUVIS® Now Covered by OptumRx
“We are pleased to announce the addition of EYSUVIS to OptumRx’s commercial formularies, which represents a significant milestone towards our goal of ensuring broad market access,” said Todd Bazemore, Chief Operating Officer of Kala Pharmaceuticals. “More than 88 million people with commercial health insurance now have access to EYSUVIS. We anticipate this figure will continue to grow from our ongoing efforts with Commercial and Medicare Part D health plans, as we work towards our ultimate goal of delivering broad payer coverage for EYSUVIS to the millions of people in the United States who su
May 27, 2021 08:00 am ET
Kala Pharmaceuticals to Present at Jefferies 2021 Virtual Healthcare Conference
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the Jefferies 2021 Virtual Healthcare Conference. Management is scheduled to participate in a fireside chat on Thursday, June 3, 2021 at 10:00 am ET.
May 20, 2021 04:01 pm ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company's 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
May 06, 2021 08:00 am ET
Kala Pharmaceuticals to Present at BofA Securities 2021 Healthcare Conference
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the BofA Securities 2021 Healthcare Conference. Management is scheduled to participate in a Fireside Chat on Thursday, May 13, 2021 at 4:15 pm ET.
May 05, 2021 07:01 am ET
Kala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update.
Apr 28, 2021 08:00 am ET
Kala Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report first quarter 2021 financial results on Wednesday, May 5, 2021. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET.
Mar 18, 2021 04:01 pm ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Mar 16, 2021 08:00 am ET
Kala Pharmaceuticals Announces Preferred Position for EYSUVIS™ on Cigna
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that Cigna has added EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% as a preferred brand on its commercial formulary, effective May 15, 2021.
Mar 02, 2021 08:00 am ET
Kala Pharmaceuticals to Present at Upcoming Investor Conferences in March
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that management will participate in the following virtual healthcare investor conferences in March.
Feb 25, 2021 07:00 am ET
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update.
Feb 18, 2021 08:00 am ET
Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report fourth quarter and full year 2020 financial results on Thursday, February 25, 2021. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET.
Feb 17, 2021 04:01 pm ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Feb 16, 2021 07:00 am ET
Kala Pharmaceuticals Announces EYSUVIS™ Now Covered by Express Scripts
Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that Express Scripts, one of the leading pharmacy benefit managers (PBM) in the United States, has added EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% to its National Preferred, Basic and High Performance Formularies, effective February 5, 2021. EYSUVIS is the first and only prescription therapy approved specifically for the short-term (up to two weeks) treatment of the signs and symptom
Jan 20, 2021 04:01 pm ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Jan 07, 2021 07:00 am ET
Kala Pharmaceuticals Announces Availability of EYSUVISTM for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline
Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced the launch of EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. EYSUVIS is now available in national and regional U.S. pharmaceutical distribution centers. Patients with a prescription can access EYSUVIS through their local retail pharmacies or through home delivery.
Jan 04, 2021 08:00 am ET
Kala Pharmaceuticals to Present at Upcoming Investor Conferences in January
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will participate in two investor conferences in January.
Dec 18, 2020 04:01 pm ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Nov 18, 2020 04:05 pm ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Nov 16, 2020 07:00 am ET
Kala Pharmaceuticals Provides Update on Launch Plans for EYSUVISTM for the Treatment of Dry Eye Disease
Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today provided an update on its plans to launch EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease.
Nov 11, 2020 08:00 am ET
Kala Pharmaceuticals to Present at the Jefferies 2020 Virtual London Healthcare Conference
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the Jefferies 2020 Virtual London Healthcare Conference. Mark Iwicki, Chairman and Chief Executive Officer of Kala Pharmaceuticals, is scheduled to participate in a fireside chat on Tuesday, November 17, 2020 at 2:05 p.m. GMT (9:05 a.m. ET).
Nov 05, 2020 07:00 am ET
Kala Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the third quarter ended September 30, 2020 and provided a corporate update.
Oct 29, 2020 08:00 am ET
Kala Pharmaceuticals to Report Third Quarter 2020 Financial Results and Host Conference Call
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report third quarter 2020 financial results on Thursday, November 5, 2020. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET.
Oct 27, 2020 07:00 am ET
Kala Pharmaceuticals Announces FDA Approval of EYSUVIS™ for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that the U.S. Food and Drug Administration (FDA) has approved EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease.
Oct 19, 2020 04:05 pm ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Sep 18, 2020 04:05 pm ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to a new employee as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Sep 10, 2020 08:00 am ET
Kala Pharmaceuticals to Host Key Opinion Leader Symposium on Unmet Need in Dry Eye Disease and Potential for EYSUVIS™
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will host a key opinion leader symposium on the unmet need in dry eye disease and the potential for EYSUVIS™ as a short-term treatment for the signs and symptoms of the disease. The event will be held virtually on Thursday, September 17, 2020, beginning at 8:00 a.m. ET.
Sep 08, 2020 08:00 am ET
Kala Pharmaceuticals to Present at Upcoming Investor Conferences in September
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that members of its management team will participate virtually in the following upcoming conferences:
Aug 06, 2020 07:00 am ET
Kala Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the second quarter ended June 30, 2020.
Aug 04, 2020 08:00 am ET
Kala Pharmaceuticals to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference. Todd Bazemore, Chief Operating Officer of Kala Pharmaceuticals, is scheduled to present on Tuesday, August 11, 2020 at 1:10 p.m. ET.
Jul 30, 2020 04:01 pm ET
Kala Pharmaceuticals to Report Second Quarter 2020 Financial Results and Host Conference Call
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report second quarter 2020 financial results on Thursday, August 6, 2020. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET.
Jul 17, 2020 04:01 pm ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Jun 10, 2020 08:00 am ET
Kala Pharmaceuticals Announces Virtual-Only Format for 2020 Annual Meeting of Stockholders
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that its 2020 Annual Meeting of Stockholders (including any adjournments or postponements, the “Annual Meeting”) has been changed to a virtual-only format. This decision reflects public health and safety concerns related to the novel coronavirus (COVID-19) pandemic and governmental restrictions limiting the number of people who may gather together, and is intended to support the health and well-being o
May 27, 2020 08:00 am ET
Kala Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the Jefferies Virtual Healthcare Conference. Mark Iwicki, Chairman, President and Chief Executive Officer of Kala Pharmaceuticals, is scheduled to participate in a fireside chat on Wednesday, June 3rd, 2020 at 8:30 a.m. ET.
May 26, 2020 08:00 am ET
Kala Pharmaceuticals Announces FDA Acceptance of New Drug Application for EYSUVIS™ for Dry Eye Disease
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) resubmission for EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%, its product candidate for the short-term treatment of the signs and symptoms of dry eye disease. The FDA stated that the NDA resubmission is a complete, Class 2 response to the Complete Response Letter (CRL) issue
May 07, 2020 07:00 am ET
Kala Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
“The first quarter of 2020 was marked by substantial progress across our business, even as we contended with the uncertainties and unprecedented disruptions imposed by the COVID-19 pandemic,” said Mark Iwicki, Chairman, President and Chief Executive Officer of Kala Pharmaceuticals. “In March, we announced positive results from our STRIDE 3 clinical trial of EYSUVIS, demonstrating statistically significant improvements in both the signs and symptoms of dry eye disease. These results replicated the positive results from prior trials, which highlight the potential of EYSUVIS to be the first presc
May 06, 2020 08:00 am ET
Kala Pharmaceuticals to Present at BofA Securities 2020 Health Care Conference
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the virtual BofA Securities 2020 Health Care Conference. Mark Iwicki, Chairman, President and Chief Executive Officer of Kala Pharmaceuticals, is scheduled to present a corporate overview on Wednesday, May 13th, 2020 at 4:20 p.m. ET.
May 04, 2020 08:00 am ET
Kala Pharmaceuticals Resubmits New Drug Application for EYSUVIS™ for Dry Eye Disease
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%, its product candidate for the short-term treatment of the signs and symptoms of dry eye disease. Kala believes this application will be considered a Class 2 resubmission, with a targeted six-month review timeline under the Prescription Dr
Apr 30, 2020 08:00 am ET
Kala Pharmaceuticals to Report First Quarter 2020 Financial Results and Host Conference Call
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report first quarter 2020 financial results on Thursday, May 7, 2020. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET.
Apr 17, 2020 04:01 pm ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Apr 03, 2020 04:01 pm ET
Kala Pharmaceuticals Announces Exercise of Underwriters’ Option to Purchase Additional Shares
Kala Pharmaceuticals, Inc. (“Kala”) (NASDAQ:KALA) today announced that the underwriters of its previously announced underwritten public offering of common stock, which closed on March 13, 2020, have exercised a portion of their option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions. After giving effect to the sale of 979,371 additional shares of common stock in the option closing, the total number of shares of common stock sold by Kala in the offering increased to 16,979,371 shares, which resulted in aggregate gross procee
Mar 10, 2020 11:02 pm ET
Kala Pharmaceuticals Announces Pricing of Public Offering of 16,000,000 Shares of Common Stock
Kala Pharmaceuticals, Inc. (“Kala”) (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, announced today the pricing of an underwritten public offering of 16,000,000 shares of its common stock at a public offering price of $7.89 per share, before underwriting discounts and commissions. The offering will result in aggregate gross proceeds of approximately $126.2 million to Kala, before deducting underwriting discounts and commissions and offering expenses. Kala also granted the underwriters of the
Mar 10, 2020 04:44 pm ET
Kala Pharmaceuticals Announces Proposed Public Offering of Common Stock
Kala Pharmaceuticals, Inc. (“Kala”) (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, announced today that it has commenced an underwritten public offering of $100.0 million of its common stock. Kala also intends to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional 15% of the shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions. The offering is subject to market and
Mar 09, 2020 06:00 am ET
Kala Pharmaceuticals Announces Statistically Significant Results for Primary and Key Secondary Endpoints in STRIDE 3 Clinical Trial Evaluating EYSUVIS™ for Signs and Symptoms of Dry Eye Disease
Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced positive topline results from STRIDE 3, a Phase 3 clinical trial evaluating KPI-121 0.25%, which Kala plans to commercialize under the brand name EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%, for the treatment of dry eye disease. STRIDE 3 met both of its primary efficacy endpoints, demonstrating a statistically significant improvement in the symptom endpoint of ocular discomfort s
Feb 20, 2020 04:01 pm ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted a non-statutory stock option to a new employee as an inducement award outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Feb 12, 2020 07:00 am ET
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2019.
Feb 06, 2020 08:00 am ET
Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it will report fourth quarter and full year 2019 financial results on Wednesday, February 12, 2020. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET.
Jan 15, 2020 08:00 am ET
Kala Pharmaceuticals Announces Completion of Enrollment of STRIDE 3 Trial for EYSUVIS™ (KPI-121 0.25%) for Dry Eye Disease
Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it has completed enrollment in its STRIDE 3 (STRIDE – Short Term Relief In Dry Eye) Phase 3 clinical trial for KPI-121 0.25%, its product candidate for the short-term treatment of dry eye disease. If approved, Kala plans to commercialize KPI-121 0.25% under the brand name EYSUVIS™. Kala is targeting to report top-line results from this trial du
Jan 08, 2020 08:00 am ET
Kala Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Mark Iwicki, Chairman, President and Chief Executive Officer of Kala Pharmaceuticals, is scheduled to present a corporate overview on Wednesday, January 15, 2020 at 11:30 a.m. PT (2:30 p.m. ET).
Dec 19, 2019 04:05 pm ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Nov 19, 2019 04:05 pm ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Nov 07, 2019 07:00 am ET
Kala Pharmaceuticals Reports Third Quarter 2019 Financial Results
Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today reported financial results for the third quarter ended September 30, 2019.
Nov 04, 2019 04:30 pm ET
Kala Pharmaceuticals to Report Third Quarter 2019 Financial Results and Host Conference Call
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it will report third quarter 2019 financial results on Thursday, November 7, 2019. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET.
Oct 21, 2019 04:05 pm ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to two new employees as an inducement award outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Sep 19, 2019 04:05 pm ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted a non-statutory stock option to one new employee as an inducement award outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Aug 29, 2019 08:00 am ET
Kala Pharmaceuticals to Present at Two Upcoming Investor Conferences in September
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that members of its management team will participate in the following upcoming conferences in September:
Aug 20, 2019 04:05 pm ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Aug 08, 2019 04:01 pm ET
Kala Pharmaceuticals Receives FDA Complete Response Letter for KPI-121 0.25% NDA and Plans to Respond with Data From STRIDE 3 Trial
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that it received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Company’s new drug application (NDA) for KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease. The FDA indicated that efficacy data from an additional clinical trial will be needed to support a resubmission.
Aug 06, 2019 07:00 am ET
Kala Pharmaceuticals Reports Second Quarter 2019 Financial Results
Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today reported financial results for the second quarter ended June 30, 2019.
Jul 30, 2019 04:05 pm ET
Kala Pharmaceuticals to Report Second Quarter 2019 Financial Results and Host Conference Call
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it will report second quarter 2019 financial results on Tuesday, August 6, 2019. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET.
Jun 20, 2019 04:05 pm ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
May 30, 2019 08:00 am ET
Kala Pharmaceuticals to Present at Jefferies 2019 Healthcare Conference
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it will present at the Jefferies 2019 Healthcare Conference in New York, NY. Mark Iwicki, Chairman, President and Chief Executive Officer of Kala Pharmaceuticals, is scheduled to present a corporate overview on Thursday, June 6, 2019 at 2:30 p.m. ET.
May 17, 2019 04:05 pm ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
May 09, 2019 07:00 am ET
Kala Pharmaceuticals Reports First Quarter 2019 Financial Results
Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today reported financial results for the first quarter ended March 31, 2019.
May 07, 2019 08:00 am ET
Kala Pharmaceuticals to Present at Bank of America Merrill Lynch 2019 Health Care Conference
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it will present at the Bank of America Merrill Lynch 2019 Health Care Conference in Las Vegas, NV. Mark Iwicki, Chairman, President and Chief Executive Officer of Kala Pharmaceuticals, is scheduled to provide a corporate overview on Tuesday, May 14, 2019 at 8:15 a.m. PT (11:15 a.m. ET).
May 02, 2019 08:00 am ET
Kala Pharmaceuticals to Report First Quarter 2019 Financial Results and Host Conference Call
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it will report first quarter 2019 financial results on Thursday, May 9, 2019. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET.
Apr 18, 2019 04:05 pm ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Apr 08, 2019 07:40 am ET
Research Report Identifies Dean Foods, Kala Pharmaceuticals, Buckeye Partners, Rockwell Medical, United Fire Group, and Clearwater Paper with Renewed Outlook — Fundamental Analysis, Calculating Forwar
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Dean Foods Company (NYSE:DF), Kala Pharmaceuticals, Inc. (NASDAQ:KALA),...
Apr 01, 2019 08:00 am ET
Kala Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it will present at the H.C. Wainwright Global Life Sciences Conference in London, U.K. Todd Bazemore, Chief Operating Officer, is scheduled to provide a corporate overview on Monday, April 8, 2019 at 2:30 PM BST.
Mar 11, 2019 04:01 pm ET
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today reported financial results for the fourth quarter and full year ended December 31, 2018.
Mar 06, 2019 08:00 am ET
Kala Pharmaceuticals to Present at Upcoming Investor Conferences in March
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that members of its management team will present at the following upcoming conferences:
Mar 04, 2019 08:00 am ET
Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it will report fourth quarter and full year 2018 financial results on Monday, March 11, 2019. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 4:30 p.m. ET.
Feb 22, 2019 04:05 pm ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Jan 18, 2019 04:05 pm ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Jan 07, 2019 07:00 am ET
Kala Pharmaceuticals Announces the Launch of INVELTYS™ and the Hiring of a Specialty Ophthalmology Sales Organization
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced the launch of INVELTYS™ (loteprednol etabonate ophthalmic suspension) 1%, the firs
Jan 02, 2019 08:00 am ET
Kala Pharmaceuticals to Present at 37th Annual J.P. Morgan Healthcare Conference
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Mark Iwicki, Chairman, President and Chief Executive Officer of Kala Pharmaceuticals, is scheduled to present a corporate overview on Monday, January 7th, 2019 at 10:30 a.m. PT (1:30 p.m. ET)
Dec 28, 2018 07:20 am ET
Detailed Research: Economic Perspectives on American Airlines Group, Sandstorm Gold, Kala Pharmaceuticals, Adecoagro S.A, Novagold Resources, and Atossa Genetics — What Drives Growth in Today's Compet
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of American Airlines Group Inc. (NASDAQ:AAL), Sandstorm Gold Ltd (NYSE:SAND),...
Dec 26, 2018 07:00 am ET
Kala Pharmaceuticals Announces New Drug Application for KPI-121 0.25% for Dry Eye Disease Has Been Accepted for Review by the U.S. Food and Drug Administration
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that the New Drug Application (NDA) for KPI-121 0.25%, a product candidate for th
Dec 19, 2018 04:05 pm ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Nov 23, 2018 08:00 am ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Nov 08, 2018 07:30 am ET
Kala Pharmaceuticals Reports Third Quarter 2018 Financial Results
Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today reported financial results for the third quarter ended September 30, 2018.
Nov 07, 2018 04:05 pm ET
Kala Pharmaceuticals to Present at the Jefferies 2018 London Healthcare Conference
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it will present at the Jefferies 2018 London Healthcare Conference in London, U.K.. Todd Bazemore, Chief Operating Officer at Kala Pharmaceuticals, will provide a corporate overview on Wednesday, November 14, 2018 at 2:00 PM GMT.
Oct 25, 2018 08:00 am ET
Kala Pharmaceuticals Appoints Steven Zhang as Vice President of Medical Affairs
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced the appointment of Steven Zhang, M.D., Ph.D., as Vice President of Medical Affairs
Oct 24, 2018 08:55 am ET
New Research Coverage Highlights Vmware, Kala Pharmaceuticals, El Pollo Loco, Integer, AAC, and Vectren — Consolidated Revenues, Company Growth, and Expectations for 2018
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Vmware, Inc. (NYSE:VMW), Kala Pharmaceuticals, Inc. (NASDAQ:KALA), El...
Oct 19, 2018 04:05 pm ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Oct 18, 2018 08:00 am ET
Kala Pharmaceuticals to Present at the 2018 American Academy of Ophthalmology (AAO) Annual Meeting and at the Ophthalmology Innovation Summit at AAO
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that it will present at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology (OIS@AAO) meeting taking place on October 25, 2018. Data from a Phase 3 clinical trial conducted with KPI-121 0.25% for the short-term treatment of dry eye disease an
Oct 16, 2018 08:00 am ET
Kala Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for KPI-121 0.25% for Dry Eye Disease
Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), today announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for KPI-121 0.25%, a topical product candidate which, if approved, could be the first FDA-approved product for the temporary relief of signs and symptoms of dry eye disease.
Oct 11, 2018 04:01 pm ET
Kala Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
Kala Pharmaceuticals, Inc. (“Kala”) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, announced today that the underwriters of its previously announced public offering have exercised in full their option to purchase an additional 1,125,000 shares of common stock at the public offering price of $8.25 per share, less underwriting discounts. After giving effect to the option closing, the total number of shares sold by Kala in
Oct 03, 2018 08:00 am ET
Kala Pharmaceuticals Announces Pricing of Public Offering of 7,500,000 Shares of Common Stock
Kala Pharmaceuticals, Inc. (“Kala”) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, announced today the pricing of an underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $8.25 per share, before offering discounts. The offering will result in aggregate gross proceeds of approximately $61.9 million to Kala, before deducting underwriting discounts and offering expenses. Kala al
Oct 02, 2018 04:18 pm ET
Kala Pharmaceuticals Announces Financing from Athyrium Capital Management Totaling $110 Million
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, today announced the closing of Kala’s $110 million credit facility with funds managed by Athyrium Capital Management, LP, a leading healthcare focused investment firm.
Oct 02, 2018 04:18 pm ET
Kala Pharmaceuticals Announces Proposed Public Offering of Common Stock
Kala Pharmaceuticals, Inc. (“Kala”) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, announced today that it has commenced an underwritten public offering of 7,500,000 shares of its common stock. Kala also intends to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,125,000 shares of common stock offered in the public offering at the public offering price, less the
Sep 21, 2018 04:05 pm ET
Kala Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Aug 31, 2018 07:50 am ET
Research Report Identifies Holly Energy Partners, First Merchants, Enbridge Energy Management, Activision Blizzard, Coherus BioSciences, and Kala Pharmaceuticals with Renewed Outlook — Fundamental Ana
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Holly Energy Partners, L.P. (NYSE:HEP), First Merchants Corporation...
Aug 29, 2018 04:01 pm ET
Kala Pharmaceuticals to Present at Upcoming Investor Conferences
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, today announced that members of its management team will participate in the following upcoming conferences:
Aug 23, 2018 01:46 pm ET
Kala Pharmaceuticals Announces FDA Approval of INVELTYS™ for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, today announced that the U.S. Food and Drug Administration (FDA) has approved INVELTYSTM (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery. INVELTYS is the first twice-daily (BID) ocular corticosteroid approved for this indication.
Aug 09, 2018 07:00 am ET
Kala Pharmaceuticals Reports Second Quarter 2018 Financial Results
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapies using its proprietary mucus-penetrating particle (MPP) technology with an initial focus on the treatment of eye diseases, today reported financial results for the second quarter ended June 30, 2018.
Aug 08, 2018 04:05 pm ET
Kala Pharmaceuticals to Present at the Wedbush PacGrow Healthcare Conference
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced that it will present at the 2018 Wedbush PacGrow Healthcare Conference in New York, NY. Mark Iwicki, Chairman and Chief Executive Officer at Kala Pharmaceuticals, will provide a corporate overview on Wednesday, August 15, 2018 at 9:45 AM ET.
Jul 31, 2018 08:00 am ET
Kala Pharmaceuticals Announces Dosing of First Patient in Phase 3 STRIDE 3 Trial of KPI-121 0.25% in Patients with Dry Eye Disease
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, today announced that the first patient has been dosed in STRIDE 3 (Short Term Relief In Dry Eye), its Phase 3 trial of KPI-121 0.25% for the short-term treatment of dry eye disease.
Jul 27, 2018 07:55 am ET
Recent Analysis Shows Kala Pharmaceuticals, Integer, Carnival, Coty, Sykes Enterprises, and Agilent Technologies Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Kala Pharmaceuticals, Inc. (NASDAQ:KALA), Integer Holdings Corporation...
Jun 19, 2018 04:01 pm ET
Kala Pharmaceuticals Announces Update to KPI-121 0.25% Development Plan
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today provided an update on the development plan for KPI-121 0.25%, which if approved could be the first FDA-approved product for the short-term treatment of dry eye disease.
May 22, 2018 07:55 am ET
Market Trends Toward New Normal in Meredith, Weis Markets, Kala Pharmaceuticals, Fortress Transportation and Infrastructure Investors, Kraton, and Web.com Group — Emerging Consolidated Expectations, A
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Meredith Corporation (NYSE:MDP), Weis Markets, Inc. (NYSE:WMK), Kala...
May 10, 2018 07:00 am ET
Kala Pharmaceuticals Reports First Quarter 2018 Financial Results
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology with an initial focus on the treatment of eye diseases, today reported financial results for the quarter ended March 31, 2018.
May 09, 2018 05:05 pm ET
Kala Pharmaceuticals Strengthens Commercial Organization in Preparation for First Product Launch
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced the following key commercial hires in preparation for the potential approval and launch of INVELTYSTM, a twice-daily steroid eye drop in development for the treatment of inflammation and pain following ocular surgery:
May 08, 2018 08:00 am ET
Kala Pharmaceuticals to Present at Upcoming Investor Conferences
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced that Mark Iwicki, Chairman and Chief Executive Officer, will provide a corporate overview at the Bank of America Merrill Lynch 2018 Health Care Conference and the Jefferies 2018 Global Healthcare Conference. Details of the presentations are as follows:
Apr 09, 2018 04:05 pm ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced that in connection with the appointment of Eric Trachtenberg as General Counsel and Corporate Secretary, the Company granted Mr. Trachtenberg an inducement award outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Apr 09, 2018 08:00 am ET
Kala Pharmaceuticals to Present at the 2018 American Society of Cataract and Refractive Surgery Annual Meeting (ASCRS) and at the Ophthalmology Innovation Summit at ASCRS
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced that it will be presenting at the Spotlight on Dry Eye session at the Ophthalmology Innovation Summit at the American Society of Cataract and Refractive Surgery Annual Meeting (OIS@ASCRS) taking place on April 12, 2018. Data from the Phase 3 clinical trials conducted with INVELTYS™ (KPI-121 1%), a topical twice-a-day product
Apr 03, 2018 08:00 am ET
Kala Pharmaceuticals Appoints Eric Trachtenberg as General Counsel and Corporate Secretary
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced the appointment of Eric Trachtenberg as General Counsel and Corporate Secretary.
Mar 28, 2018 08:10 am ET
Recent Analysis Shows Welltower, Integer, Jernigan Capital, ZTO EXPRESS INC, Kala Pharmaceuticals, and Covenant Transportation Group Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, March 28, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Welltower Inc. (NYSE:WELL), Integer Holdings Corporation...
Mar 26, 2018 07:00 am ET
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today reported financial results for the fourth quarter and full year 2017.
Mar 19, 2018 08:00 am ET
Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced that it will release fourth quarter and full year 2017 financial results on Monday, March 26, 2018. Kala will host a live conference call and webcast at 8:00 AM ET to provide a general business update and discuss the Company’s 2017 financial results.
Mar 14, 2018 08:00 am ET
Kala Pharmaceuticals to Present at the Oppenheimer 28th Annual Healthcare Conference
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced that it will present at the Oppenheimer 28th Annual Healthcare Conference in New York, NY. Todd Bazemore, Chief Operating Officer at Kala Pharmaceuticals, will provide a corporate overview on Wednesday, March 21, 2018 at 10:55 AM ET.
Mar 05, 2018 08:00 am ET
Kala Pharmaceuticals Appoints Gregory Perry to Board of Directors and as Audit Committee Chair
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced the appointment of Gregory Perry to the Company’s Board of Directors and Chair of its Audit Committee.
Jan 25, 2018 08:10 am ET
New Research: Key Drivers of Growth for Comstock Resources, Varonis, Union Bankshares, Heidrick & Struggles International, Tejon Ranch, and Kala Pharmaceuticals — Factors of Influence, Major Initiativ
NEW YORK, Jan. 25, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Comstock Resources, Inc. (NYSE:CRK), Varonis Systems,...
Jan 05, 2018 07:00 am ET
Kala Pharmaceuticals Announces Topline Results for Two Phase 3 Trials (STRIDE 1 and STRIDE 2) of KPI-121 0.25% in Dry Eye Disease
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced topline results from its two Phase 3 clinical trials, STRIDE 1 and STRIDE 2 (STRIDE - Short Term Relief In Dry Eye), evaluating the safety and efficacy of KPI-121 0.25% versus placebo in patients with dry eye disease.
Jan 05, 2018 06:50 am ET
Kala Pharmaceuticals Announces New Drug Application for INVELTYSTM (KPI-121 1%) Has Been Accepted for Review by the U.S. Food and Drug Administration
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced that the New Drug Application (NDA) for INVELTYSTM (KPI-121 1%), a topical twice-a-day product candidate for the treatment of inflammation and pain in patients who have undergone ocular surgery, has been accepted for review by the United States Food and Drug Administration (FDA). The FDA, in its 74-day letter, indi
Nov 13, 2017 08:00 am ET
Kala Pharmaceuticals Appoints Todd Bazemore as Chief Operating Officer
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced the appointment of Todd Bazemore as Chief Operating Officer of the Company. He will report directly to Mark Iwicki, Chairman and Chief Executive Officer of Kala Pharmaceuticals and is expected to join Kala on November 20, 2017.
Nov 07, 2017 07:30 am ET
Kala Pharmaceuticals Reports Third Quarter 2017 Financial Results And Provides Business Update
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today reported financial results for the third quarter and nine months ended September 30, 2017 and provided an update on business progress.
Oct 25, 2017 08:00 am ET
Kala Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for INVELTYSTM (KPI-121 1%)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) today announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for INVELTYSTM (KPI-121 1%), a topical twice-a-day product candidate for the treatment of inflammation and pain in patients who have undergone ocular surgery. If approved, Kala expects INVELTYS would be the first twice-daily ocular corticosteroid indicated for the treatment of post-operative ocular inflammation and pain. The brand name for KPI-121 1%, INVELTYS, has been

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.